Remynd Secures €3.5M to Advance Alzheimer’s Drug REM392 to Clinical Trials

Belgian biotech company Remynd has received a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation to advance its septin-modulating drug REM392 into clinical trials for patients with mild-to-moderate Alzheimer’s disease. This funding supports the development of a potential new treatment targeting Alzheimer’s.

Originally published by gnews